

How to manipulate p53 isoform to restore tumour suppressor activity


Jean-Christophe (JC) Bourdon, PhD
Fellow, Breast Cancer Campaign, 2012-2017

Cancer Research Division
Dundee Cancer Centre
University of Dundee



Introduction

- *p53* is one of the most frequently mutated genes in human cancers (International Cancer Genome Consortium)
- *p53* KO mice are cancer prone
- Cancer-prone families who develop several types of cancer, particularly in children and young adults (Li-Fraumeni syndrome) present germ-line mutation of the *p53* gene.





In absence of cellular stress

p53



Cellular stress

(DNA damage, virus,
oncogene activation,
Hypoxia, pH, temp.)



RRRCWWGYYY (0-13bp) RRRCWWGYYY (0-13 bp) RRRCWWGYYY (0-13bp) RRRCWWGYYY
R=G/A, W=A/T, Y=C/T (23808 ways to write a p53RE)

{ El-Deiry et al., 1992 }
{ Bourdon et al., 1997 }



Problem:


It is still difficult in clinical studies to link p53 mutation status to:

- cancer prognosis
- cancer treatment


p53 mutation status can be associated with poor prognosis

Kaplan-Meier survival curves

Overall survival



Disease Free survival



Consider the pattern RRR-C-WW-G-YYY where R, W & Y can all take on one of the values A, C, G or T.
 For R, permitted values are A & G, while C & T are incorrect.
 For W, permitted values are A & T, while C & G are incorrect.
 For Y, permitted values are C & T, while A & G are incorrect.

Since each of the R, W & Y components can take on 4 different values there are $4^8 [= 2^{16} = 65536]$ different possible combinations. We wish to count the number of mistakes that can occur in the pattern.

We wish to identify the number of different combinations of R, W & Y which contain precisely k mistakes, for k=0to3.

Suppose that the pattern contains k mistakes. There are 8C_k different ways of fixing k of the 8 components to be incorrect, and each component can be incorrect in just 2 ways, while each of the remaining (8-k) components is correct in 2 ways.
 Therefore there are just ${}^8C_k * 2^k * 2^{(8-k)} = 2^8 * {}^8C_k = \mathbf{256 * {}^8C_k}$ ways in which **k** precisely errors can occur.

The following table shows the values obtained.

k	8C_k	$256 * {}^8C_k$
0	1	256
1	8	2048
2	28	7168
3	56	14336
		Total 23808 ways to write a p53RE: RRRCWWGYYY


Note that, by definition, ${}^nC_k = \frac{n!}{k!(n-k)!}$ so that ${}^8C_k = \frac{8!}{k!(8-k)!}$ where $r! = 1*2*3* \dots *r$ is the product of the first **r** integers. The term r! is pronounced r-factorial.

Questions about p53:

- 1- How one protein, p53, can be responsive to so many stress signals at once?
- 2- How can p53 specifically bind to so many p53REs, different in DNA sequences and DNA structure?
- 3- How do p53 “decide” the target genes to be expressed in order to trigger a coordinated and defined cellular response adapted to the damages and the tissue type ?



The International Cancer Genome Consortium



Within a decade, it will be possible to better tailor treatment

- Develop gene tests to routinely group patients
- Find new drugs that target specific groups better










































p53 is the most frequently mutated gene in large variety of human cancers










































<http://www.sanger.ac.uk/genetics/CGP/cosmic>

	mutation	tumours	%
TP53	22505	69620	32.33
KRAS	22720	98127	23.15
EGFR	10649	49455	21.53
Braf	20002	100844	19.83
CDKN2A	3910	24818	15.75
PTEN	2358	18300	12.89
PIK3CA	3611	29094	12.41
IDH1	3194	27936	11.43
RB1	362	3827	9.46
NRAS	2647	33500	7.90
HRAS	765	22015	3.47
c-met	162	5932	2.73
ERBB2	157	9930	1.58
Akt1	134	9274	1.44



p53 plays a pivotal role in cancer formation and progression

Tissue	Point Mutations	
	% Mutated	Tested
Adrenal gland		190
Autonomic ganglia		553
Biliary tract		622
Bone		702
Breast		11460
Central nervous system		5529
Cervix		1200
Endometrium		1128
Eye		200
Fallopian tube		2
Gastrointestinal tract (site indeterminate)		1
Genital tract		31
Haematopoietic and lymphoid		9428
Kidney		1332
Large intestine		12611
Liver		3198
Lung		6542
Meninges		215
NS		264
Oesophagus		3732
Ovary		3675
Pancreas		1356
Parathyroid		16
Penis		24
Peritoneum		44
Pituitary		37
Placenta		24
Pleura		147
Prostate		1312
Salivary gland		300
Skin		2671
Small intestine		143
Soft tissue		1609
Stomach		3707
Testis		163
Thymus		74
Thyroid		565
Upper aerodigestive tract		5195
Urinary tract		3757
Vagina		28
Vulva		164

Tissue	Point Mutations	
	% Mutated	Tested
Adrenal gland		349
Autonomic ganglia		602
Biliary tract		2405
Bone		386
Breast		3521
Central nervous system		1998
Cervix		751
Endometrium		2846
Eye		254
Fallopian tube		3
Gastrointestinal tract (site indeterminate)		1043
Genital tract		31
Haematopoietic and lymphoid		8561
Kidney		1256
Large intestine		51735
Liver		1115
Lung		24908
Meninges		118
NS		366
Oesophagus		1232
Ovary		5215
Pancreas		7220
Parathyroid		116
Penis		28
Peritoneum		152
Pituitary		300
Placenta		9
Pleura		118
Prostate		1624
Salivary gland		363
Skin		2919
Small intestine		568
Soft tissue		1809
Stomach		4095
Testis		441
Thymus		194
Thyroid		6751
Upper aerodigestive tract		2573
Urinary tract		1461
Vagina		3
Vulva		35




Questions about p53:

- 1- How one protein, p53, can be responsive to so many stress signals at once?
- 2- How can p53 specifically bind to so many p53REs, different in DNA sequences and DNA structure?
- 3- How do p53 “decide” the target genes to be expressed in order to trigger a coordinated and defined cellular response adapted to the damages and the tissue type ?

-> Is p53 “really” the only protein able to transactivate genes through p53 responsive element in response to various cellular stresses ?



p63 and p73 proteins are homologous to p53 protein



p63 and p73 proteins:

- contain a p53 DNA binding domain
- bind specifically to p53RE
- transactivate p53-inducible promoters in response to stress


Human p63 gene structure



Mutation of the p63 gene or loss of the p63 gene induce developmental defects




Ectrodactyly patients




p63 -/- mouse

p63 and cancer






- p63 gene is rarely mutated in human cancer.
- ΔNp63 isoforms are overexpressed in head and neck, lung, ovarian and nasopharynx tumours and are associated with poor outcome
- ΔNp63 isoform expression is associated with chemoresistance in breast tumours and head&neck tumours
- TAp63 induce cellular senescence and inhibit cell proliferation
- Decreased TAp63 expression is associated with metastasis and poor outcome in bladder and breast cancers.
- TAp63 impair metastasis formation.
- p53 tumour suppressor activity is reduced in p63/p73 deficient mice (Flores et al., (2005) Cancer Cell 7: 363-373.)

Human p73 gene structure



b) p73 protein isoforms






$\Delta N'$ p73 2 3 3' or



p73 KNOCK OUT MICE EXHIBIT MULTIPLE DEFECTS



Somatic growth defects
Chronic inflammation, infection
Hydrocephalus
Hippocampal dysgenesis
Defects in pheromone detection

Yang, A. et al.
p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours.
Nature 404, 99-103 (2000).

p73 and cancer

-TAp73 -/- mice are cancer prone (genomic instability). Δ Np73 isoform inhibits DNA-damage response pathway

– Δ Np73-/- mice are hypersensitive to DNA damaging agents through p53-mediated apoptosis

-p73 gene is rarely mutated in human cancer.

– Δ Ex2p73 and/or Δ Ex2/3p73 isoforms are frequently overexpressed in many human cancers (liver, ovarian, breast, vulvar, melanoma) (misregulation of alternative splicing)


– Δ Np73 isoforms are upregulated in many human cancers (neuroblastoma, hepatocarcinoma, glioma, lung, esophageal, ALL, ovarian)

- p53 tumour suppressor activity is reduced in p63/p73 deficient mice (Flores et al., (2005) Cancer Cell 7: 363-373.)


**Is p53 gene really so
different from the p63 and p73 genes ?**

(Bourdon et al., 2005, Genes&Dev)

a) Generacer PCR on human *p53* mRNA




b) Structure of the human *p53* gene




The *p53* gene structure is conserved through evolution


Marcel et al., 2011, Cell Death Diff
Khouri et al., 2011, Genes & Cancer





p53 isoforms are expressed in normal human tissues in a tissue dependent manner



Human p53 gene




Human p53 protein isoforms





Nomenclature : p53 isoform workshop at IARC in Lyon, September 2010


SK-N-AS (p53R342X)





SK-N-AS cell growth




SK-N-AS (p53R342X)





SK-N-AS cell growth




SK-N-AS (p53R342X)





SK-N-AS cell growth



SK-N-AS (p53R342X)






SK-N-AS cell growth



Alteration of the ratio mutant p53/p53 isoform can trigger cancer cell death

MDA-231 (p53R280K)





1st International p53 Isoforms Meeting, IARC, Lyon, France, 13-15 September 2010



(Bourdon et al., 2005, Gene & Dev)

120 scientists coming from 26 countries attended the meeting <http://www.iarc.fr/p53isoforms/>



-drosophila, zebrafish, mouse animal models

-human stem cells, human cancer cells




(Bourdon et al., 2005, Gene & Dev)





Human p53 protein isoforms





p53 β and p53 γ modulate p53 α transcriptional activity in a promoter dependent manner



p53 isoform expression is associated with breast cancer prognosis





Human p53 protein isoforms




$\Delta 133p53\beta$ expression is associated with poor disease free-survival.

10% of primary breast tumours have gain of expression of $\Delta 133p53\beta$





MDA231-D3H2LN cells are more metastatic than MDA-231 cells and overexpress mutant $\Delta 133$ p53 isoforms

A





B




WT or mutant $\Delta 133$ p53 isoforms confer cell motility to breast cancer cells

A




WT or mutant $\Delta 133$ p53 isoforms confer cell motility to colon cancer cells


A




C



B




D




Loss of p53 promotes cell migration and invasion in 3D matrices

*Gadea G, de Toledo M, Anguille C, Roux P.
J Cell Biol. 2007 Jul 2;178(1):23-30*


WTp53 MEF



p53^{-/-} MEF




**$\Delta 133p53\beta$ induces cell
motility**




WT $\Delta 133p53\beta$ binds directly to $\Delta Np63$ isoforms and potentiates repression of E-cadherin expression in luminal breast cancer cells (MCF7)


A







B





C






Mutant $\Delta 133p53\beta$ binds directly to TAp63 β isoforms and inhibits TAp63 β transcriptional activity on E-cadherin promoter in triple-negative breast cancer cells (MDA231-D3H2LN)







Human p53 protein isoforms








$\Delta 133p53\alpha$ does not inhibit p53-mediated G2 cell cycle arrest in response to doxorubicin





$\Delta 133p53\alpha$ inhibits p53-mediated apoptosis and G1 cell cycle arrest in response to doxorubicin



$\Delta 133p53\alpha$ inhibits p53-mediated transactivation of p21 probably through direct interaction with p53




$\Delta 133p53\alpha$ does NOT act exclusively as an inhibitor of p53




Tumor conditioned medium from U87 cells transfected with si Δ 133p53 impairs HUVEC endothelial cell migration and tube formation



B1



B2 Tubulogenesis quantification
(U87 conditioned media)




siRNA treated U87 in CAM model



Δ133p53 isoforms favour *in vivo* angiogenesis

Assessment of pro-angiogenic genes expression




Δ 133p53 regulate ANG and MDK expression. ANG independently of p53


p53 isoforms regulate cell response to damage and cell differentiation signalling

- p53 isoforms regulate cell cycle progression, senescence, cell death, cell differentiation, cell migration and invasion, angiogenesis, embryo development and ageing.
- Wild-type and mutant p53 isoforms oligomerise with each other and with p63 and p73 isoforms
- p53 isoforms bind differentially to promoter region
- p53 isoforms modulate gene expression (mRNA and microRNA).
- p53 isoform expression is abnormal in several types of cancer
- p53 isoform expression is associated with prognosis of breast cancer patient

Cellular stress
(DNA damage, virus,
oncogene activation,
Hypoxia, pH, temp.)



RRRCWWGYYY (0-13bp) RRRCWWGYYY



RRRCWWGYYY (0-13bp) RRRCWWGYYY (0-13 bp) RRRCWWGYYY (0-13bp) RRRCWWGYYY
R=G/A, W=A/T, Y=C/T (23808 ways to write a p53RE)

Cell death

Cell cycle
arrest

Questions about p53:

1- How one protein, p53, can be responsive to so many stress signals at once?

- p53 is not one protein, it is composed of a family of proteins encoded by p53, p63 and p73 genes that are differentially expressed in a tissue dependent manner.

2- How can p53 specifically bind to so many p53REs, different in DNA sequences and DNA structure?


- p53/p63/p73 protein isoforms can form oligomers which transactivate different promoters

3- How do p53 “decide” the target genes to be expressed in order to trigger a coordinated and defined cellular response adapted to the damages and the tissue type ?



Axololt

p53 is required for organ regeneration in vertebrates



Effect of pifithrin- α on limb regeneration. (A & E) Controls treated daily with DMSO. (B-D & F-G) Pifithrin- α treated animals (5 μ M pifithrin- α , added freshly diluted everyday). Limbs in panels A-D were amputated distally in the middle of the zeugopod and limbs in panels E-G were amputated proximally through the middle of the stylopod (see dotted lines in panels A & E for amputation levels).

***BMC Evolutionary Biology* 2007, 7:180**

Urodele p53 tolerates amino acid changes found in p53 variants linked to human cancer

Éric Villiard¹, Henner Brinkmann¹, Olga Moiseeva¹, Frédérick A Mallette¹, Gerardo Ferbeyre^{*1,2} and Stéphane Roy^{*1,2}

University of Dundee, Ninewells hospital, Jacqui Wood Cancer Centre, Dundee Cancer Centre

- Kenneth Fernandes
- Marie Khoury
- Alexandra Diot
- Sylvanie Surget
- Sebastien Jo
- Valerie Meuray

Former team members

- Virginie Marcel
- Olivier Terrier
- Mustapha Aoubala
- Alice Machado da Silva
- Hayley Moore (PhD)
- Hugo Bernard (PhD)
- Fiona Murray-Zmijewski (PhD)

Collaborations

- David Lane (A-star, Singapore))
- Curtis Harris (NIH, Washington)
- Bjorn Gjertsen (Bergen Hospital, Norway)
- Gerry Zambetti (St Jude Children Hospital, Memphis)
- Grahame Hardie (University of Dundee)
- Borek Vojtesek (University of Brno, Czech Rep.)
- Franck Toledo (Institut Curie, France)
- Pierre Roux (CNRS Montpellier, France)
- Herve Bonnefoi (Hospital Bergonie, Bordeaux, France)

- Surgeons
 - Alastair Thompson
 - Robert Steele

